Larotinib structure
|
Common Name | Larotinib | ||
---|---|---|---|---|
CAS Number | 1438072-11-7 | Molecular Weight | 488.94 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C24H26ClFN4O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of LarotinibLarotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1]. |
Name | Larotinib |
---|
Description | Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1]. |
---|---|
Related Catalog | |
Target |
EGFRL861Q:0.423 nM (IC50) EGFRL858R:0.563 nM (IC50) EGFR (WT):0.611 nM (IC50) EGFRT790M:45.2 nM (IC50) HER4:84 nM (IC50) BLK:102 nM (IC50) IRAK1:167 nM (IC50) BTK:196 nM (IC50) HER2:253 nM (IC50) |
In Vivo | 每日给 Larotinib mesylate 后,SD 大鼠无不良反应水平 (NOAEL) 为 10 mg/kg, 比格犬最低不良反应水平 (LOAEL) 为 5 mg/kg。最大耐受剂量 (MTDs) 在 SD 大鼠和比格犬中分别为 20 和 25 mg/kg[1]。 Larotinib mesylate 显示出剂量依赖性的抗肿瘤结果,在肿瘤小鼠模型中,18 mg/kg 肿瘤抑制率超过 60% (数据未发表)[1]。 |
References |
Molecular Formula | C24H26ClFN4O4 |
---|---|
Molecular Weight | 488.94 |